

1 The effectiveness of Evodia rutaecarpa hot compress on the recovery of gastrointestinal
2 function after laparoscopic surgery for colorectal cancer: A propensity score-matched
3 retrospective cohort study

4

5 MiaoXin Huang^{1¶}, JunMiao Li^{3¶}, Wei Huang^{3&}, YuLin Zhou^{4&}, Lei Cai^{4*}, Ming Liu^{2*}

6

7 ¹Faculty of Health Sciences and Sports, Macao Polytechnic University, Macao SAR,

8 China

9

10 ²Peking University Health Science Center - Macao Polytechnic University Nursing

11 Academy, Macao Polytechnic University, Macao SAR, China

12

13 ³The Second Affiliated Hospital of Guangzhou University of Chinese Medicine,

14 Guangzhou, Guangdong, China

15

16 ⁴The Third Affiliated Hospital of Sun Yat sen University, Guangzhou, Guangdong,

17 China

18

19 ^{#a}Peking University Health Science Center - Macao Polytechnic University Nursing

20 Academy, Macao Polytechnic University, Macao SAR, China

21

22 ^{#b}The Second Affiliated Hospital of Guangzhou University of Chinese Medicine,

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 Guangzhou, Guangdong Province, China

24

25 *Corresponding author

26 Email: karryliu@mpu.edu.mo

27 Email: cailei.0105@163.com

28

29 ¶These authors contributed equally to this work.

30 &These authors also contributed equally to this work.

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50 **Abstract**

51 **Background**

52 Although the use of hot compresses with the herbal medicine *Evodia rutaecarpa* (ER)
53 as a complementary and alternative therapy to promote recovery of postoperative
54 gastrointestinal function is gradually increasing in clinical practice, there is still a lack
55 of relevant empirical studies. Particularly, the role of ER hot compress therapy on
56 gastrointestinal recovery post-laparoscopic surgery for colorectal cancer has not been
57 well investigated. The purpose of this study is to evaluate the efficacy and applicability
58 of ER hot compress therapy for the recovery of postoperative gastrointestinal function.

59 **Methods**

60 This is a retrospective cohort study. Patients were divided into two cohorts, the ER
61 group and the non-ER group. Propensity score matching(PSM) was introduced to limit
62 confounding, and independent samples t-tests, non-parametric tests, or Chi-squared
63 tests were used to compare these two cohorts.

64 **Results**

65 A total of 454 patients were included, with 267 (59%) receiving ER hot compress
66 therapy and 187 (41%) not. Following 1:1 PSM, 320 patients were analyzed (160 in
67 each group). Compared to the ER group, patients in the non-ER group had shorter times
68 to return to a semi-liquid diet ($p=0.035$) and hospital stay ($p=0.001$), as well as lower
69 hospital costs ($p<0.001$). Subgroup analyses revealed no statistically significant
70 differences in the length of hospital stay, hospital costs, postoperative time to return to
71 full-liquid diet, or time to return to semi-liquid diet among stage I and II tumor patients,

72 though means and standard deviations were generally lower in the ER group.
73 Complication incidence showed no significant difference between the two cohorts
74 before and after PSM.

75 **Conclusions**

76 The use of ER hot packs after laparoscopic surgery in patients with colorectal cancer
77 has a non-significant effect on the recovery of the gastrointestinal function and, given
78 the results of the study, it is likely that patients with early-stage tumors may benefit
79 more. Therefore, healthcare providers need to consider the individualisation,
80 practicality, and economics of treatment options.

81 **Keywords:** Colorectal cancer, Laparoscopy, Evodia rutaecarpa, Hot compress therapy,
82 Propensity score

83

84 **Introduction**

85 The World Health Organization (WHO) has released the latest estimates of the
86 global cancer burden, showing that colorectal cancer (CRC) is the third most common
87 cancer worldwide (over 1.9 million cases, 9.6%) and the second leading cause of cancer
88 deaths (over 0.9 million cases, 9.3%)^[1]. In addition, the World Health Organization's
89 colorectal cancer epidemiological data for the whole of 2022 show that Asia ranks first
90 in terms of colorectal cancer incidence, mortality, and 5-year prevalence (colon,
91 rectum), followed by Europe with the second highest share^[2]. Studies have shown
92 that the incidence and mortality of CRC have decreased in some European, Oceanian
93 and North American countries in recent years ^[3-5], but data from the Chinese Cancer

94 Center in 2022 show that the incidence and mortality of CRC continue to increase [3, 6-
95 7]. Worryingly, the incidence of colorectal cancer is steadily increasing in China and
96 globally in people under the age of 50 [8-14]. Therefore, the prevention and treatment of
97 colorectal cancer are urgent, and various treatment regimes and technologies have
98 emerged. The surgical procedures have been moved from traditional open surgery to
99 laparoscopic surgery and robotic-assisted laparoscopic surgery.

100 However, postoperative colorectal cancer patients still face various challenges.
101 Among them, postoperative gastrointestinal dysfunction (POGD) is one of the common
102 complications of abdominal surgery, including laparoscopic colorectal cancer surgery
103 [15]. The most commonly occurring symptoms of POGD are nausea, vomiting,
104 abdominal distention, postoperative intestinal ileus (POI), gastrointestinal bleeding,
105 and possibly progressive multi-organ failure[5]. Therefore, a variety of complementary
106 and alternative therapies have been used to help restore gastrointestinal function after
107 surgery, particularly a range of herbal medicines.

108 In the past few years, *Evodia rutaecarpa* (ER), also known as Wuzhuyu (a type of
109 herbal medicine), has received increasing attention from various health professionals in
110 mitigating discomfort and supporting recovery from POGD. ER was first described
111 more than 2000 years ago in the *Shennong Ben Cao Jing* (a Chinese book on agriculture
112 and medicinal plants)[16]. Nowadays, herbal therapy has attracted worldwide
113 attention[17]. As an herbal remedy with potential value for CRC patients, ER is worth
114 exploring in depth. In China, the use of ER hot compress therapy is becoming
115 increasingly popular..

116 Based on the literature review, a study by Li and his colleagues showed that the
117 evodiamine and the rutaecarpine derived from ER have high permeability and
118 remarkable selective transdermal properties^[18]. Furthermore, Gu and his colleagues
119 stated that sesquiterpenoids have significant pharmacological activities and suggested
120 that the volatile oil of *Cornus officinale* can pass through PTGS1, PTGS2 and IL-6^[19].
121 Because of these properties, ER is mixed with coarse salt in equal proportions to make
122 an ER hot compress bag in clinical practice, heated in a microwave oven at medium
123 heat for 4 minutes, and then applied to the patient's navel or Shenque point.

124 In the implementation of complementary and alternative therapies, not only
125 doctors and rehabilitation therapists, but also nurses play an essential role. Therefore,
126 when implementing complementary and alternative therapies, nurses should
127 proactively understand their efficacy and applicability, use scientific and effective
128 nursing practice based on evidence-based nursing, and strive to be patient advocates.

129 Therefore, this retrospective cohort study focused on colorectal cancer patients
130 undergoing laparoscopy to investigate the effect of ER hot compress therapy on the
131 recovery of postoperative gastrointestinal function.

132

133 **Materials and method**

134 **Study design and data source**

135 This was a retrospective cohort study based on the Strengthening the Reporting of
136 Observational Studies in Epidemiology (STROBE) guidelines (See S1 File.)^[20-21]. The
137 study was approved by the Ethics Committee of Macao Polytechnic University

138 (approval number: FCSD/MSN-0051/2023) and the Institutional Review Board of the
139 Second Affiliated Hospital of Guangzhou University of Chinese Medicine (approval
140 number: ZE2023-459-01), and individual written informed consent was not required.
141 The study was conducted in accordance with the principles of the Declaration of
142 Helsinki, and the investigators collected electronic medical records of colorectal cancer
143 patients who underwent laparoscopic surgery at the Second Affiliated Hospital of
144 Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of
145 Chinese Medicine) from December 1, 2016 to December 30, 2022, including patient
146 demographics, perioperative data, and other information. Throughout the study, patient
147 data were de-identified (recorded and stored in a coded form).

148 **Study sample**

149 All data was collected from December 21st, 2023 to February 10th, 2024. The
150 study population was selected based on the following inclusion criteria: 1) meet the
151 diagnostic criteria for CRC in the 2017 edition of the Chinese Standards for the
152 Diagnosis and Treatment of CRC and further confirmed by pathological biopsy^[22]; 2)
153 all participants underwent elective standard laparoscopic radical tumor curettage; 3) the
154 age of patients was between 25 and 80 years; 4) participants signed informed consent
155 for surgery and use of complementary and alternative therapies (herbal ER hot iron
156 therapy).

157 The exclusion criteria for the study were: 1) a confirmed diagnosis of distant
158 metastasis of the tumor; 2) combination with other malignant tumors; 3) physical
159 disability that prevents cooperation with functional exercises; 4) mental illness or

160 cognitive impairment that makes communication with the participant difficult; 5)
161 pregnancy or breastfeeding; 6) patients undergoing abdominal surgery within 6 months
162 and having severe intestinal adhesions; 7) patients with unsatisfactory control of the
163 primary medical disease; 8) concurrent other serious organic diseases; 9) preoperative
164 abdominal infection; 10) patients requiring postoperative blood transfusion; 11)
165 patients requiring open surgery or extended radical surgery; 12) undergoing combined
166 abdominal perineal radical rectal cancer surgery (Miles procedure); 13) patients
167 experiencing serious complications within 6 hours of surgery or requiring admission to
168 intensive care after surgery; 14) patients with allergy to herbal ER therapy.

169 **Definition and measurement of exposure factors and outcome**

170 **indicators**

171 Patients were divided into two groups according to the exposure factor (i.e.
172 whether they received ER hot compress treatment after laparoscopic surgery for CRC):
173 the ER group and the conventional treatment group (the non-ER group).

174 1) The non-ER group only received routine postoperative care, including
175 monitoring of vital signs, postoperative fluid restoration, care of drainage tubes and
176 monitoring of drainage fluids, pain relief, surgical wound care and daily care.

177 2) The ER group received ER hot compress therapy and routine postoperative care.
178 250 grams of ER (from Guangdong Kangmei Pharmaceutical Co., Ltd.) and 250 grams
179 of coarse salt (Guangzhou Salt Industry Co., Ltd.) were placed in a cotton bag of 18
180 cm x23 cm and heated in a microwave oven at medium heat for 2 to 3 minutes. The
181 temperature of the ER hot pack was about 60 - 70 °C , and tolerable to the patient.

182 Nurses massage the ER hot pack in a clockwise direction with the Shenque point (navel)
183 as the centre for 20 circles, avoiding the surgical incision. The ER hot compress
184 treatment is usually started 24 hours after surgery, twice a day for 20 minutes each time.

185 3) Postoperative gastrointestinal outcomes and their measurements: time of first
186 postoperative flatus, time of first postoperative defecation, and time of recovery of
187 postoperative bowel sounds (the actual measurement of the above three items is
188 recorded from the end of the operation to the time when the doctor asks the patient
189 about the event, and it is not possible to calculate the exact time when the patient has
190 the above events), time of full-liquid diet and time of semi-liquid diet (the actual
191 measurement time is from the end of the operation to the time when the doctor gives
192 the order, i.e. the time when the patient starts the full-liquid diet) and the incidence of
193 postoperative gastrointestinal complications (including postoperative nausea and
194 vomiting, abdominal pain and bloating, anastomotic fistula, and bowel paralysis and
195 obstruction).

196 **Covariates**

197 The selection of covariates consists of three steps in this study. First, possible
198 covariates were selected based on the investigator's clinical experience and literature
199 review, including surgical site, tumor stage, history of chronic gastrointestinal disease,
200 intestinal stoma, gender, chronic lung disease, anaemia, hypoproteinaemia, history of
201 abdominal surgery, diabetes mellitus, hypertension, hyperlipidaemia, history of heart
202 disease, history of smoking, history of alcohol consumption, age, BMI, intraoperative
203 bleeding, and operative time. Second, the raw data were statistically analysed to screen

204 for possible confounders based on the grouping variable (whether ER hot compress
205 therapy was used or not). Third, different caliper values were adjusted in the R language
206 software to analyse which covariates were likely to have an effect on the study results.
207 The main covariates examined were: 1) continuous variables: age and intraoperative
208 bleeding; 2) categorical variables: hyperlipidaemia and tumor stage.

209 **Handling of missing data**

210 Firstly, the type of data missing from the Electronic Medical Record System(EMR)
211 information was analysed, such as the patient's basic information, BMI, and the time of
212 the patient's first post-operative bowel movement;

213 Secondly, the analysis concluded that the reason for the missing data collected in
214 this study was Missing Completely at Random (MCAR), due to human factors that
215 were not recorded, omitted, or lost, and did not affect the unbiased nature of the sample:
216 1) it was divided into the following cases, and if there were more, the researcher simply
217 deleted them; 2) if there were fewer missing values, those missing values were filled
218 by interpolation using the mean and the plurality of the missing values.

219 **Statistical methods**

220 R4.2.3 software and SPSS 27.0 were used for statistical analysis. Measures that
221 conformed to normal distribution and homogeneity of variances were expressed as
222 mean standard deviation (mean \pm SD) and independent t-test was used for comparison
223 between two groups, while those that did not conform to normal distribution were
224 expressed as median (interquartile range), i.e. M (Q1, Q3) and Mann-Whitney U-test
225 was used for comparison between two groups. Count data were expressed as cases (%)

226 and comparisons between two groups were made using the Pearson chi-squared test or
227 Fisher's exact test. All statistical inferences were made using two-tailed tests with a
228 statistically significant test level of $\alpha=0.05$ and 95% CI for parameter CI estimation.

229 **Propensity score matching**

230 To assess the impact of confounding bias due to non-randomisation in
231 observational studies, propensity score matching (PSM) was proposed in this study<sup>[23-
232 24]</sup>. Four variables, tumor stage, hyperlipidaemia, intraoperative bleeding and age, were
233 used as covariates, and the use of ER hot packs was used as a grouping
234 variable(exposure factor). Propensity scores were calculated for each sample using
235 nearest neighbour 1:1 matching and a caliper value of 0.05. In addition, the
236 investigators visually compared the distribution difference of the two data sets before
237 and after matching by plotting distribution plots, density plots, and empirical
238 cumulative distribution function (eCDF) plots, respectively.

239 **Sensitivity analysis**

240 First, the parameters of the sensitivity analysis were determined, and common
241 parameters included caliper values and matching ratios^[25]. The researcher evaluates and
242 compares the matching results under different caliper values (e.g. selecting different
243 caliper values of 0.02, 0.03, 0.05, 0.1, and 0.2; as well as selecting different matching
244 ratios (e.g. ratio=1 and ratio=2) and also compares the matching results under different
245 matching variables).

246 Second, the robustness and sensitivity of the PSM results can be assessed by
247 comparing the sample sizes after matching under different parameter settings by

248 statistically analysing the results, and by assessing the distribution of the scores after
249 matching by plotting distribution plots and histograms. It is assumed that the variation
250 of the matching results under different parameter settings and different matching
251 variables is small, which indicates that the matching results are less sensitive to the
252 choice of parameters and have better robustness and sensitivity.

253 **Equilibrium test**

254 Equilibrium tests are used to assess whether the baseline characteristics between
255 the two data groups (ER and non-ER groups) before and after PSM are effectively
256 balanced. Commonly used equilibrium tests include the Standardised Mean Difference
257 (SMD), the Chi-square test, and the t-test^[26-27]. The SMD was used in this study to
258 assess the effect of adjustment. If the SMD value is small (less than 0.1), it means that
259 the matching effect is good, the confounding factors between the two groups have been
260 effectively controlled, and the research results are credible. In addition, SMD plots and
261 histograms were used to visually analyse the baseline distribution of data between the
262 two groups before and after matching.

263 **Subgroup analysis**

264 To further explore the heterogeneity of the samples after PSM, to analyse the
265 variability of different treatments, and to improve the accuracy and reliability of the
266 results, the researchers performed subgroup analyses of the pooled data. Because tumor
267 staging is usually clinically relevant to the patient's postoperative treatment plan.
268 Therefore, according to the American Joint Committee on Cancer (AJCC) cancer

269 staging system^[28] and the diagnosis of clinicians, tumor staging was divided into
270 different subgroups for analysis.

271

272 **Results**

273 **The process of study population selection**

274 Fig. 1 Flowchart of sample selection

275 **Before PSM**

276 Before matching, there were 267 cases in the ER group and 187 cases in the non-
277 ER group. Statistical analysis was performed on the final 454 patients enrolled
278 (statistical values represent T value, U value, and chi-square value, respectively). This
279 analysis indicated that, firstly, the p-values for age and hyperlipidemia were 0.015 and
280 0.008, respectively, indicating statistical significance and potential impact on the results.
281 Secondly, compared to the non-ER group, patients in the ER group had higher hospital
282 costs ($p < 0.001$), longer hospital stays ($p < 0.001$), and longer time to resume a semi-
283 liquid diet after surgery ($p = 0.021$). The remaining results showed no statistical
284 significance (see Table 1 and S.Table 1) and other additional information is provided
285 in S.Table 2.

286 Table 1 Baseline data before PSM

Variables	Total (n = 454)	ER group (n = 267)	Non-ER group (n = 187)	p	statistic
Surgical Site, n (%)				0.758	0.095

Variables	Total (n = 454)	ER group (n = 267)	Non-ER group (n = 187)	p	statistic
Colon =1	164 (36.1)	98 (36.7)	66 (35.3)		
Rectum = 2	290 (63.9)	169 (63.3)	121 (64.7)		
Tumor-staging, n (%)				0.250	4.104
I = 1	48 (10.6)	28 (10.5)	20 (10.7)		
II = 2	83 (18.3)	41 (15.4)	42 (22.5)		
III = 3	85 (18.7)	54 (20.2)	31 (16.6)		
unspecified = 4	238 (52.4)	144 (53.9)	94 (50.3)		
HCGD, n (%)				0.697	0.152
NO = 0	170 (37.4)	98(36.7)	72 (38.5)		
YES = 1	284 (62.6)	169 (63.3)	115 (61.5)		
Intestinal stoma, n (%)				0.911	0.012
NO = 0	307 (67.6)	180 (67.4)	127 (67.9)		
YES = 1	147 (32.4)	87 (32.6)	60 (32.1)		
Gender, n (%)				0.960	0.003
Male = 1	247 (54.4)	145 (54.3)	102 (54.5)		

Variables	Total (n = 454)	ER group (n = 267)	Non-ER group (n = 187)	p	statistic
Female = 2	207 (45.6)	122 (45.7)	85 (45.5)		
CLD, n (%)				0.947	0.004
NO = 0	297 (65.4)	175 (65.5)	122 (65.2)		
YES = 1	157 (34.6)	92 (34.5)	65 (34.8)		
Anemia, n (%)				0.861	0.031
NO = 0	390 (85.9)	230 (86.1)	160 (85.6)		
YES = 1	64 (14.1)	37 (13.9)	27 (14.4)		
Hypoproteinemia, n (%)				0.760	0.093
NO = 0	422 (93.0)	249 (93.3)	173 (92.5)		
YES = 1	32 (7.0)	18 (6.7)	14 (7.5)		
HAS, n (%)				0.890	0.019
NO = 0	339 (74.7)	200 (74.9)	139 (74.3)		
YES = 1	115 (25.3)	67 (25.1)	48 (25.7)		
Diabetes, n (%)				0.793	0.069
NO = 0	391 (86.1)	229 (85.8)	162 (86.6)		
YES = 1	63 (13.9)	38 (14.2)	25 (13.4)		

Variables	Total (n = 454)	ER group (n = 267)	Non-ER group (n = 187)	p	statistic
Hypertension, n (%)				0.983	0.000
NO = 0	328 (72.2)	193 (72.3)	135 (72.2)		
YES = 1	126 (27.8)	74 (27.7)	52 (27.8)		
Hyperlipidemia, n (%)				0.008	7.075
NO = 0	353 (77.8)	196 (73.4)	157 (84.0)		
YES = 1	101 (22.2)	71 (26.6)	30 (16.0)		
HHD, n (%)				0.257	1.284
NO = 0	302 (66.5)	172 (64.4)	130 (69.5)		
YES = 1	152 (33.5)	95 (35.6)	57 (30.5)		
Smoking History, n (%)				0.534	0.387
NO = 0	349 (76.9)	208 (77.9)	141 (75.4)		
YES = 1	105 (23.1)	59 (22.1)	46 (24.6)		
Drinking History, n (%)				0.728	0.121
NO = 0	401 (88.3)	237 (88.8)	164 (87.7)		

Variables	Total (n = 454)	ER group (n = 267)	Non-ER group (n = 187)	p	statistic
YES = 1	53 (11.7)	30 (11.2)	23 (12.3)		
Age, Mean \pm SD	60.31 \pm 9.88	59.37 \pm 10.32	61.65 \pm 9.09	0.015	2.433
BMI, Mean \pm SD	22.91 \pm 2.99	22.84 \pm 3.03	23.01 \pm 2.93	0.568	0.572
Intraoperative					
Hemorrhage_ml,	50 (50, 100)	50 (50, 100)	50 (30, 100)	0.841	24696
Median (Q1,Q3)					
Operative Time_h,	4.00(3.46,	4.00(3.50, 4.67)	3.92(3.33, 4.73)	0.491	24018
Median (Q1,Q3)					
	4.67)				
Hospital					
Costs_CNY,	73733.17 \pm	75429.63 \pm	71310.96 \pm	<	-4.198
Mean \pm SD					
	10823.33	11426.93	9409.44	0.001	
Length of Hospital					
Stay_d,	15.5 (14, 18)	16 (14, 19)	15 (13, 17)	0.001	20514
Median (Q1,Q3)					
NEBS,					
	10 (0, 16)	16 (12, 20)	0 (0, 0)	<	0
Median (Q1,Q3)					
				0.001	
TFPE_d,	1.83 (1.61,	1.85 (1.64, 2.69)	1.80 (1.60, 2.68)	0.101	22706.5
Median (Q1,Q3)					
	2.68)				

Variables	Total (n = 454)	ER group (n = 267)	Non-ER group (n = 187)	p	statistic
TFPD_d, Median (Q1,Q3)	4.59 (2.64, 5.74)	4.63 (2.69, 5.66)	4.52 (2.58, 5.83)	0.545	24131
TRNBSAS_d, Median (Q1,Q3)	4.87 (4.61, 6.58)	4.90 (4.72, 6.68)	4.81 (3.61, 5.93)	0.002	20789
TFFFAS_d, Mean ± SD	4.33 ± 2.18	4.44 ± 2.04	4.16 ± 2.35	0.173	-1.356
TFSFAS_d, Mean ± SD	6.77 ± 2.80	7.03 ± 2.91	6.41 ± 2.59	0.021	-2.318
Postoperative Complications, n (%)				0.856	0.033
NO = 0	404 (89.0)	237 (88.8)	167 (89.3)		
YES = 1	50 (11.0)	30 (11.2)	20 (10.7)		

287 *Notes:* HCGD: History of Chronic Gastrointestinal Disease, HAS: History of
288 Abdominal Surgery, HHD: History of Heart Disease, CLD: Chronic Lung Disease,
289 TFPE: Time For First Postoperative Exhaust, TFPD: Time For First Postoperative
290 Defecation, TRNBSAS: Time to resuming normal bowel sounds after surgery, TFFFAS:
291 Time For First Full-liquid Feeding After Surgery, TFSFAS: Time For First Semi-liquid
292 Feeding After Surgery.

293 **After PSM**

294 The data of 454 patients underwent propensity score matching (PSM) analysis
295 using the nearest neighbor method, with age, tumor stage, intraoperative hemorrhage,
296 and hyperlipidemia as matching variables. Age and hyperlipidemia were identified as
297 potential confounding factors before matching, while tumor stage and intraoperative
298 hemorrhage became statistically significant after adjusting for a smaller caliper value
299 and were thus included as matching variables. The matching ratio was 1:1, with a
300 caliper set at 0.05, resulting in successful matching of 320 patients, including 160 in
301 the ER group and 160 in the non-ER group.

302 Before PSM, there were significant differences between the ER and non-ER
303 groups in terms of age and hyperlipidemia (with p-values of 0.041 and 0.008,
304 respectively), indicating potential confounding factors. However, after PSM, the
305 differences between the ER and non-ER groups in all characteristics became non-
306 significant (all $P > 0.05$, as detailed in Table 2), indicating successful achievement of
307 balanced comparability after PSM.

308 Additionally, the Jitter Plot (see Fig. 2) illustrated that, after matching, the
309 distributions of matching variables between the ER and non-ER groups tended to be
310 consistent, indicating a good matching effect. The Density Plot and Empirical
311 Cumulative Distribution Function Plot (eCDF plot) (refer to S1 Fig. and S2 Fig.)
312 demonstrated that the density curves or cumulative distribution curves of the two
313 groups' data were close to each other after matching, further validating the effectiveness
314 of the matching method.

315 As shown in Table 2, after PSM, there were statistically significant differences in
 316 postoperative gastrointestinal function recovery indicators between the two groups of
 317 patients. Compared to the ER group, the non-ER group had a shorter time to restore
 318 bowel sounds postoperatively (p=0.002) and an earlier initiation of a semi-liquid diet
 319 (p=0.022). Furthermore, compared to the ER group, the non-ER group had lower
 320 hospital costs (p<0.001) and shorter length of stay (p=0.001) (See S1 Table. for
 321 additional information).

322 Table 2 Baseline data after PSM

Variables	Total (n = 320)	ER group (n = 160)	Non-ER group (n = 160)	p	statistic
Surgical Site, n (%)				0.818	0.053
Colon =1	122 (38.1)	62 (38.8)	60 (37.5)		
Rectum = 2	198 (61.9)	98 (61.3)	100 (62.5)		
Tumor staging, n (%)				1.127	0.771
I = 1	30 (9.4)	13 (8.1)	17 (10.6)		
II = 2	57 (17.8)	30 (18.8)	27 (16.9)		
III = 3	54 (16.9)	25 (15.6)	29 (18.1)		
unspecified = 4	179 (55.9)	92 (57.5)	87 (54.4)		
HCGD, n (%)				0.251	1.317

Variables	Total (n = 320)	ER group (n = 160)	Non-ER group (n = 160)	p	statistic
NO = 0	124 (38.8)	57 (35.6)	67 (41.9)		
YES = 1	196 (61.3)	103 (64.4)	93 (58.1)		
Intestinal Stoma, n (%)				0.545	0.366
NO = 0	221 (69.1)	113 (70.6)	108 (67.5)		
YES = 1	99 (30.9)	47 (29.4)	52 (32.5)		
Gender, n (%)				0.575	0.314
Male = 1	171 (53.4)	88 (55.0)	83 (51.9)		
Female = 2	149 (46.6)	72 (45.0)	77 (48.1)		
CLD, n (%)				1.000	0
NO = 0	210 (65.6)	105 (65.6)	105 (65.6)		
YES = 1	110 (34.4)	55 (34.4)	55 (34.4)		
Anemia, n (%)				0.623	0.242
NO = 0	277 (86.6)	140 (87.5)	137 (85.6)		
YES = 1	43 (13.4)	20 (12.5)	23 (14.4)		
Hypoproteinemia,				1.000	0

Variables	Total (n = 320)	ER group (n = 160)	Non-ER group (n = 160)	p	statistic
n (%)					
NO = 0	302 (94.4)	151 (94.4)	151 (94.4)		
YES = 1	18 (5.6)	9 (5.6)	9 (5.6)		
HAS, n (%)				0.899	0.016
NO = 0	237 (74.1)	118 (73.75)	119 (74.4)		
YES = 1	83 (25.9)	42 (26.25)	41 (25.6)		
Diabetes, n (%)				0.741	0.110
NO = 0	278 (86.9)	140 (87.5)	138 (86.3)		
YES = 1	42 (13.1)	20 (12.5)	22 (13.8)		
Hypertension, n (%)				0.899	0.016
NO = 0	237 (74.1)	118 (73.75)	119 (74.4)		
YES = 1	83 (25.9)	42 (26.25)	41 (25.6)		
Hyperlipidemia, n (%)				1.000	0
NO = 0	260 (81.25)	130 (81.25)	130 (81.25)		
YES = 1	60 (18.75)	30 (18.75)	30 (18.75)		

Variables	Total (n = 320)	ER group (n = 160)	Non-ER group (n = 160)	p	statistic
HHD, n (%)				0.228	1.455
NO = 0	220 (68.75)	105 (65.6)	115 (71.9)		
YES = 1	100 (31.25)	52 (34.4)	45 (28.1)		
Smoking History, n (%)				0.789	0.072
NO = 0	248 (77.5)	125 (78.1)	123 (76.9)		
YES = 1	72 (22.5)	35 (21.9)	37 (23.1)		
Drinking History, n (%)				0.210	1.572
NO = 0	285 (89.1)	146 (91.3)	139 (86.9)		
YES = 1	35 (10.9)	14 (8.8)	21 (13.1)		
Postoperative Complications, n (%)				1.000	0
NO = 0	296 (92.5)	148 (92.5)	148 (92.5)		
YES = 1	24 (7.5)	12 (7.5)	12 (7.5)		
Age, Mean \pm SD	59.99 \pm 9.09	59.64 \pm 9.43	60.34 \pm 8.76	0.488	0.694
BMI, Mean \pm SD	22.89 \pm 2.98	22.70 \pm 3.05	23.08 \pm 2.90	0.259	1.132

Variables	Total (n = 320)	ER group (n = 160)	Non-ER group (n = 160)	p	statistic
Intraoperative					
Hemorrhage_ml,	50 (50, 100)	50 (50, 100)	50 (30, 100)	0.161	11669.5
Median (Q1,Q3)					
Operative Time_h,	3.91 (3.42,	3.92(3.50,	3.90 (3.30,		
Median (Q1,Q3)	4.62)	4.65)	4.61)	0.507	12251.5
Hospital Costs_CNY,	72435.17 ±	74856.62 ±	70013.72 ±	<	
Mean ± SD	10123.06	11208.38	8256.44	0.001	-4.400
Length of Hospital					
Stay_d,	15.74 ± 3.85	16.46 ± 4.048	15.01 ± 3.495	<	
Mean ± SD				0.001	-3.429
NEBS,				<	
Median (Q1,Q3)	3 (0, 16)	16 (12, 19.75)	0 (0, 0)	0.001	0
TFPE_d,	1.83 (1.60,	1.86 (1.60,	1.80 (1.60,		
Median (Q1,Q3)	2.63)	2.65)	2.60)	0.195	11728.5
TFPD_d,	4.59 (2.65,	4.64 (2.78,	4.57 (2.63,		
Median (Q1,Q3)	5.73)	5.66)	5.82)	0.439	12159.5
TRNBSAS_d,	4.86 (4.57,	4.92 (4.67,	4.80 (3.55,	0.002	10219.5

Variables	Total (n = 320)	ER group (n = 160)	Non-ER group (n = 160)	p	statistic
Median (Q1,Q3)	6.36)	6.62)	5.88)		
TFFFAS_d, Mean ± SD	4.15 ± 2.05	4.33 ± 1.99	3.98 ± 2.10	0.129	-1.522
TFSFAS_d, Mean ± SD	6.51 ± 2.48	6.81 ± 2.58	6.20 ± 2.35	0.030	-2.185

323

324

Fig. 2 Jitter plot of the ER group and non-ER group after PSM

325 **Results of sensitivity analysis**

326

The sensitivity analyses revealed that with increasing caliper values and different

327

matching ratio conditions, the sample sizes of the matched ER and non-ER groups

328

exhibited minimal variation. When the ratio was set to 1, as the caliper value increased

329

from 0.02 to 0.2 (caliper values of 0.02, 0.03, 0.1, and 0.2), the sample sizes gradually

330

increased with minor fluctuations, and the cumulative change in the number of cases

331

did not exceed 10% of the total sample size. For instance, the number of matches for

332

the ER and non-ER groups were 139/139, 150/150, 169/169, and 177/177, respectively.

333

Furthermore, when the ratio was set to 2 and the caliper value was 0.05, there were 175

334

matches for the non-ER group and 160 matches for the ER group. After matching, all

335

covariate p-values were greater than 0.05, indicating consistent results for each match

336 (see S3 Fig. and S4 Fig.).

337 Hence, this study demonstrates strong robustness in reaching consistent conclusions
338 across various matching conditions, thereby enhancing the reliability and validity of the
339 findings.

340 **Results of the equilibrium test**

341 The equilibrium and comparability of the two groups of data after PSM was
342 assessed by the Standardised Mean Differences (SMD) before and after matching (see
343 Table 3 and Fig. 3). Before matching, the SMDs of tumor stage, age and
344 hyperlipidaemia exceeded 0.1, indicating the presence of large confounding factors. In
345 contrast, after matching, the SMDs of potential confounders were all less than 0.1,
346 indicating improved sample balance. In addition, the histogram (see Fig. 4) visualised
347 that the histograms of the ER and non-ER groups showed more similar distribution
348 patterns and locations after matching, further indicating that the two groups were more
349 similarly distributed in terms of the characteristic variables and that the PSM was
350 successful in reducing the propensity bias to achieve a balanced result.

351 Table 3 SMD before and after PSM

	Before PSM	After PSM
Variables	Std. Mean Diff.	Std. Mean Diff.
Tumor staging 1	-0.0068	-0.0816
Tumor staging 2	-0.1970	0.0520
Tumor staging 3	0.0908	-0.0622
Tumor staging 4	0.0735	0.0627

Hyperlipidemia 0	-0.2388	0.0000
Hyperlipidemia 1	0.2388	0.0000
Age	-0.2210	-0.0685
Intraoperative haemorrhage_ml	-0.1678	0.0137

352

353 Fig. 3 SMD plot of ER group and non-ER group before and after PSM

354

355 Fig. 4 hist graph of ER group and non-ER group before and after PSM

356

357 Results of subgroup analysis

358 This study categorized tumor staging into four subgroups and conducted separate
359 statistical analyses for the ER group and non-ER group.

360 1) Tumor Stage I: Compared to the non-ER group, patients in the ER group had a
361 slightly longer mean time to full-liquid diet postoperatively (ER: 3.79 ± 1.25 vs non-
362 ER: 3.66 ± 1.20 ; $p=0.765$), slightly longer mean time to semi-liquid diet postoperatively
363 (ER: 6.87 ± 2.78 vs. non-ER: 5.70 ± 1.91 ; $p=0.181$), slightly longer hospital stay (ER:
364 16.23 ± 3.30 vs. non-ER: 15.18 ± 2.63 ; $p=0.338$), and slightly higher average hospital
365 costs (ER: 75132.22 ± 12657.10 vs. non-ER: 69890.67 ± 11096.58 ; $p=0.238$). However,
366 these differences between the groups were not statistically significant (see Table 4-1).

367 Table 4-1 Results of statistical analysis of dependent variables for tumor stage I

Variables	Total (n = 30)	ER group (n = 13)	Non-ER group (n = 17)	p	statistic
Hospital Costs_CNY, Mean ± SD	72162.01 ± 11883.00	75132.22 ± 12657.10	69890.67 ± 11096.58	0.238	-1.207
Length of Hospital Stay_d, Mean ± SD	15.63 ± 2.93	16.23 ± 3.30	15.18 ± 2.63	0.338	-0.976
TFFFAS_d, Mean ± SD	3.72 ± 1.20	3.79 ± 1.25	3.66 ± 1.20	0.765	-0.302
TFSFAS_d, Mean ± SD	6.21 ± 2.36	6.87 ± 2.78	5.70 ± 1.91	0.181	-1.373
Postoperative Complications, n (%)				1.00	Fisher's exact test
NO = 0	27 (90.0)	12 (92.3)	15 (88.2)		
YES = 1	3 (10.0)	1 (7.7)	2 (11.8)		

368 2) Tumor stage II: Except for hospital costs, patients in the ER group had a shorter
369 mean time to full-liquid diet after surgery (ER: 4.15 ± 1.05 vs non-ER: 5.05 ± 3.11;
370 p=0.161), a shorter average time to semi-liquid diet after surgery (ER: 6.40 ± 1.21 vs
371 non-ER: 7.35 ± 3.51; p=0.191), and a shorter average hospital costs (ER: 75576.01 ±
372 10654.74 vs non-ER: 73310.87 ± 7431.45; p=0.361), and shorter average hospital stay
373 (ER: 16.47 ± 2.69 vs. non-ER: 16.78 ± 4.68; p= 0.756) compared to the non-ER group,

374 although these differences were not statistically significant between groups (see Table
 375 4-2).

376 Table 4-2 Results of statistical analysis of dependent variables for tumor stage II

Variables	Total (n = 57)	ER group (n = 30)	Non-ER group (n = 27)	p	statistic
Hospital Costs_CNY, Mean ± SD	74503.05 ± 9259.14	75576.01 ± 10654.74	73310.87 ± 7431.45	0.361	-0.921
Length of Hospital Stay_d, Mean ± SD	16.61 ± 3.73	16.47 ± 2.69	16.78 ± 4.68	0.756	0.312
TFFFAS_d, Mean ± SD	4.57 ± 2.30	4.15 ± 1.05	5.05 ± 3.11	0.161	1.437
TFSFAS_d, Mean ± SD	6.85 ± 2.59	6.40 ± 1.21	7.35 ± 3.51	0.191	1.335
Postoperative Complications, n (%)				1.000	Fisher's exact test
NO = 0	53 (93.0)	28 (93.3)	25 (92.6)		
YES = 1	4 (7.0)	2 (6.7)	2 (7.4)		

377 3) Tumor stage III and unspecified stage: According to Table 4-3, compared with
 378 the ER group, the non-ER group had a significantly shorter postoperative time to semi-
 379 liquid diet (ER: 8.35 ± 4.19 vs. non-ER: 6.45 ± 2.33), with a statistically significant
 380 difference between the two groups ($p=0.041$); as shown in Table 4-4, compared with
 381 the ER group, the non-ER group not only had a significantly shorter postoperative time
 382 to semi-liquid diet (ER: 6.51 ± 2.18 vs. non-ER: 5.87 ± 1.85 ; $p=0.034$), but also had
 383 significantly lower hospital costs (ER: 75510.44 ± 11584.95 vs. non-ER: $69478.08 \pm$
 384 7643.31 ; $p<0.001$) and shorter hospital stays (ER: 16.29 ± 3.957 vs. non-ER: $14.47 \pm$
 385 3.154 ; $p<0.001$), with significant statistical differences between the two groups.

386 Table 4-3 Results of statistical analysis of dependent variables for tumor stage III

Variables	Total (n = 54)	ER group (n = 25)	Non-ER		p	statistic
			group (n = 29)			
Hospital Costs_CNY, Mean \pm SD	69929.01 ± 9049.86	71443.97 ± 9574.28	68623.01 ± 8522.77		0.257	-1.146
Length of Hospital Stay_d, Mean \pm SD	15.96 ± 4.74	17.20 ± 5.86	14.90 ± 3.26		0.075	-1.818
TFFFAS_d, Mean \pm SD	4.52 ± 2.20	5.10 ± 2.52	4.01 ± 1.79		0.069	-1.855
TFSFAS_d, Mean \pm SD	7.33 ± 3.43	8.35 ± 4.19	6.45 ± 2.33		0.041	-2.096

Variables	Total (n = 54)	ER group (n = 25)	Non-ER group (n = 29)	p	statistic
Postoperative Complications, n (%)				1.000	Fisher's exact test
NO = 0	49 (90.7)	23 (92.0)	26 (89.7)		
YES = 1	5 (9.3)	2 (8.0)	3 (10.3)		

387 Table 4-4 Results of statistical analysis of the dependent variable for tumor stage as
388 unspecified stage

Variables	Total (n = 179)	ER group (n = 92)	Non-ER group (n = 87)	p	statistic
Hospital Costs_CNY, Mean ± SD	72578.51± 10294.67	75510.44 ± 11584.95	69478.08 ± 7643.31	<0.001	-4.133
Length of Hospital Stay_d, Mean ± SD	15.41 ± 3.694	16.29 ± 3.957	14.47± 3.154	<0.001	-3.416
TFFFAS_d, Mean ± SD	3.98 ± 2.01	4.25 ± 2.11	3.69 ± 1.86	0.066	-1.853
TFSFAS_d, Mean ± SD	6.20 ± 2.04	6.51 ± 2.18	5.87 ± 1.85	0.034	-2.131

Variables	Total (n = 179)	ER group (n = 92)	Non-ER group (n = 87)	p	statistic
Postoperative Complications, n (%)				0.768	Fisher's exact test
NO = 0	167 (93.3)	85 (92.4)	82 (94.3)		
YES = 1	12 (6.7)	7 (7.6)	5 (5.7)		

389

390 Discussion

391 ER is characterised by its pungent nature and spicy, bitter taste with low toxicity.
 392 From a traditional Chinese medicine review, it is associated with the liver, spleen,
 393 stomach, and kidney meridians. Its effects include dispersing cold and relieving pain,
 394 reducing rebellious qi and stopping vomiting, and aiding yang tonification and stopping
 395 diarrhoea^[29]. The "Shennong Bencao Jing" also describes ER as a mildly warm herb,
 396 mainly used for warming the middle, dispelling cold, removing dampness and blood
 397 stasis, expelling wind evil and opening the body channels, and classifies it as a medium-
 398 grade herb^[16].

399 The Shen Que acupoint of the Ren meridian is located at the navel. The Ren
 400 meridian, one of the eight extraordinary meridians, intersects with the twelve ordinary
 401 meridians and serves as the hub of the meridian system, connecting hundreds of vessels
 402 and penetrating the five zang organs and six fu organs^[30-31]. Applying medicine to the

403 navel can promote circulation in the meridians, harmonise abdominal qi and relieve
404 abdominal bloating and discomfort^[31].

405 Modern research has found that during embryonic development, the navel is the
406 final site of closure of the abdominal wall, lacking subcutaneous fat but containing
407 abundant blood vessels, lymphatic vessels and nerves, making it highly permeable^{[32-}
408 ^{34]}. Therefore, drug molecules can easily penetrate the epidermal keratin layer of the
409 umbilicus, rapidly infiltrate the intercellular space and exert their effects. In clinical
410 practice, the commonly used ER hot compress therapy uses local heat to facilitate the
411 penetration of drugs such as evodiamine and rutaecarpine from the ER into the abdomen
412 (around the navel) to accelerate the recovery of post-operative gastrointestinal
413 function^[35-36].

414 This retrospective cohort study aimed to investigate the effects of using ER hot
415 compress therapy on the recovery of gastrointestinal (GI) function in patients
416 undergoing colorectal cancer surgery. Currently, most retrospective cohort studies tend
417 to directly analyse the raw data to verify the effectiveness of ER hot compress therapy.
418 However, due to limitations in study design, those studies suffer from recall bias and
419 multiple confounding factors that do not adequately account for the importance of ER
420 hot compress therapy in the recovery of postoperative gastrointestinal function. To
421 reduce these confounding factors, this study adopted the PSM method, which is
422 commonly used in clinical practice, and investigated the factors that influence the
423 efficacy of ER hot compresses. At the same time, a subgroup analysis according to
424 tumor stage was performed to gain insight into the use of the method in patients with

425 different stages of the disease.

426 The results of our study showed that when comparing patients in the ER and non-
427 ER groups, the matched results showed that there was no significant difference between
428 the two groups in terms of indicators related to gastrointestinal function after
429 laparoscopic surgery (p-values were all greater than 0.05), which was similar to the
430 results of the studies by Chen^[37] and Jian^[38]. Interestingly, however, when analysing
431 the tumor stage into subgroups according to the AJCC TNM system^[28], we found that
432 the mean postoperative recovery time on a full-liquid diet was shorter in the ER group
433 for patients with tumor stage II compared to the non-ER group (non-ER group: $5.05 \pm$
434 3.11 vs. ER group: 4.15 ± 1.05), the mean recovery time on semi-liquid diet was also
435 shorter (non-ER group: 7.35 ± 3.51 vs. ER group: 6.40 ± 1.21), and the mean length of
436 hospital stay was also shorter (non-ER group: 16.78 ± 4.68 vs. ER group: 16.47 ± 2.69).
437 Although not statistically significant, these findings imply that patients with different
438 tumor stages may differ in the therapeutic efficacy of ER hot compress therapy,
439 suggesting that postoperative patients with early-stage tumors may be a potential
440 population to benefit from ER hot compress therapy.

441 In addition, the combination of ER hot compress therapy with other
442 complementary and alternative therapies has been widely used after a variety of
443 abdominal surgeries^[39-43]. These therapies include pain management^[44], ultrasound
444 electroconductive transdermal drug delivery techniques^[45], moxibustion^[46], auricular
445 acupressure and electroacupuncture^[47-48]. The results of clinical studies have shown
446 that ER hot compress therapy combined with other therapies can not only improve the

447 symptoms of urinary retention, nausea and vomiting, abdominal distension and
448 abdominal pain in postoperative patients, but also promote the recovery of
449 gastrointestinal function in postoperative patients. However, because more than two
450 alternative therapies were combined, it was not possible to determine exactly which
451 therapy had a significant effect. Furthermore, although previous studies have explored
452 the impact of different treatment options on patient recovery, few studies have analysed
453 the cost-effectiveness of patients receiving complementary and alternative therapies
454 from an economic perspective, especially when looking at hospital costs and treatment
455 outcomes.

456 Therefore, our study filled the gap in previous research by conducting an in-depth
457 analysis of the cost-effectiveness of patients receiving complementary and alternative
458 therapies from an economic perspective. With a focus on assessing the economic impact
459 of these therapies, particular attention was paid to hospital costs, the length of hospital
460 stay and treatment outcomes. Our results indicate that patients receiving ER hot
461 compress therapy showed an overall increasing trend in hospital costs. However, further
462 analysis showed that there were no significant differences in hospital costs and the
463 length of hospital stay between the ER and non-ER groups in different tumor stage
464 subgroups (including tumor stages I and II as well as stage III), with p-values all greater
465 than 0.2. Additionally, the length of hospital stay was not statistically significant for
466 patients with tumor stage I or II ($p > 0.1$). This finding suggests that although receiving
467 ER hot compress therapy may slightly increase overall patient costs, there was no
468 apparent economic disadvantage within specific subgroups. Therefore, our study

469 highlights the considerations that healthcare practitioners need to address how to
470 effectively use treatment modalities and techniques to improve patient recovery rates
471 and reduce hospital length of stay without significantly increasing patient costs.

472 **Limitations**

473 The limitations of this study may include: (1) due to inherent methodological
474 limitations of retrospective study, the accuracy of recording time of first postoperative
475 flatus, first postoperative defecation and recovery of postoperative bowel sound was
476 limited, which may have led to bias in the assessment of recovery of postoperative
477 gastrointestinal function, potentially affecting the reliability of the study conclusions.
478 (2) there was no statistical analysis of the differences in surgical experience between
479 surgeons, nor was there a detailed investigation of potential confounding factors such
480 as age and gender. (3) some objective laboratory indicators to validate the efficacy of
481 ER hot compress therapy were not included. (4) the frequency of use of ER hot
482 compress therapy by patients was not discussed and the effect of frequency of use on
483 efficacy remains unclear. In addition, there may have been variability in the
484 implementation of ER hot compress therapy. (5) patients were not followed up, which
485 might limit understanding of post-discharge outcomes. (6) selection bias could not be
486 avoided i.e. patients with more severe conditions are more likely to choose
487 complementary and alternative therapies such as ER hot compress therapy. This may
488 lead to selection bias and might affect the results of the trial.

489 Therefore, we recommend the following.

490 First, plarger sample sizes, multicentre controlled prospective cohort studies or

491 randomised controlled trials are recommended. Second, future clinical studies on ER
492 hot compress therapy should explicitly state that the treatment team's characteristics
493 and the experiences of the surgeon to better control for potential confounding factors.
494 Third, the objective experimental indicators should be selected and not limited to
495 comparing the recovery of gastrointestinal function during hospitalisation after surgery,
496 follow-up observations, such as rehospitalisation rates and outpatient follow-up, should
497 be included to complement the assessment of postoperative recovery of gastrointestinal
498 function. Fourth, future studies should provide a more detailed record of the frequency
499 of ER hot compress therapy usage and explore how usage frequency affects treatment
500 efficacy. If possible, the overall effects on the recovery of postoperative gastrointestinal
501 function of different groups should be compared by follow-up after discharge. Finally,
502 future studies can employ qualitative research methods, such as interviewing patients
503 about their experiences of postoperative use of ER hot compress therapy, to
504 comprehensively evaluate the clinical benefits of this complementary and alternative
505 therapy.

506

507 **Conclusion**

508 The overall comparison suggests that *Evodia rutaecarpa* (ER) hot compress
509 therapy may not significantly promote recovery of gastrointestinal function, however,
510 patients with early-stage colorectal cancer may be a potential beneficiary group.
511 Therefore, healthcare providers should consider treatment diversity and patient
512 characteristics when formulating personalised treatment plans. By developing

513 treatment regimes based on scientific evidence and individual patient needs, healthcare
514 professionals can optimise treatment outcomes and effectively meet patient needs.

515

516 **Acknowledgments**

517 We would like to thank Mr. XiaoFeng Chen for his technical support and guidance.

518

519 **Supporting information**

520 S1 File. The Strengthening the Reporting of Observational Studies in Epidemiology
521 (STROBE) guidelines.

522 S1 Fig. The density plot of the ER group and non-ER group before and after PSM.

523 S2 Fig. The eCDF plot of the ER group and non-ER group before and after PSM.

524 S3 Fig. Differences in standard deviation plots of the ER group and non-ER group
525 before and after PSM under different caliper values.

526 S4 Fig. Histograms of the ER group and non-ER group before and after PSM at
527 different caliper values.

528 S1 Table. The 95% confidence intervals for continuous variables before and after PSM.

529 S2 Table. Types of postoperative complications.

530

531 **Reference**

532

[1]World Health Organization (WHO). Global cancer burden growing, amidst mounting need for services. [Accessed on 01 February 2024]. Available online:

<https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services>

- [2]World Health Organization. The Global Cancer Observatory: 2022 [Internet]. World Health Organization; 2024 Feb 8. Available from: <https://gco.iarc.who.int/media/globocan/factsheets/cancers/8-colon-fact-sheet.pdf>
- [3]Garg R, Sayre EC, Pataky R, McTaggart-Cowan H, Peacock S, Loree JM, McKenzie M, Brown CJ, Yeung SST, De Vera MA. Direct Medical Spending on Young and Average-Age Onset Colorectal Cancer before and after Diagnosis: a Population-Based Costing Study. *Cancer Epidemiol Biomarkers Prev*. 2024 Jan 9;33(1):72-79. doi: 10.1158/1055-9965.EPI-23-0498. PMID: 37878338; PMCID: PMC10774739.
- [4]Qu R, Ma Y, Zhang Z, Fu W. Increasing burden of colorectal cancer in China. *Lancet Gastroenterol Hepatol*. 2022 Aug;7(8):700. doi: 10.1016/S2468-1253(22)00156-X. PMID: 35809603.
- [5]Li S, Liu KX, Deng XM, Fang XM, Xia ZY, Wang YL, Yu JB, Li JB, Shang Y, Zhou J. Expert consensus on prevention and treatment of postoperative gastrointestinal dysfunction. *Journal of International Anesthesiology and Resuscitation*. 2021;42(11):1133-1142. DOI:10.3760/cma.j.cn321761-20210811-10003.
- [6]Feng R, Su Q, Huang X, Basnet T, Xu X, Ye W. Cancer situation in China: what does the China cancer map indicate from the first national death survey to the latest cancer registration? *Cancer Commun (Lond)*. 2023 Jan;43(1):75-86. doi: 10.1002/cac2.12393. Epub 2022 Nov 17. PMID: 36397729; PMCID:

PMC9859730.

- [7]Wang Z, Dan W, Zhang N, Fang J, Yang Y. Colorectal cancer and gut microbiota studies in China. *Gut Microbes*. 2023 Jan-Dec;15(1):2236364. doi: 10.1080/19490976.2023.2236364. PMID: 37482657; PMCID: PMC10364665.
- [8]Abualkhair WH, Zhou M, Ahnen D, Yu Q, Wu XC, Karlitz JJ. Trends in Incidence of Early-Onset Colorectal Cancer in the United States Among Those Approaching Screening Age. *JAMA Netw Open*. 2020 Jan 3;3(1):e1920407. doi: 10.1001/jamanetworkopen.2019.20407. Erratum in: *JAMA Netw Open*. 2020 Feb 5;3(2):e201038. PMID: 32003823; PMCID: PMC7042874.
- [9]GBD 2019 Colorectal Cancer Collaborators. Global, regional, and national burden of colorectal cancer and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Gastroenterol Hepatol*. 2022 Jul;7(7):627-647. doi: 10.1016/S2468-1253(22)00044-9. Epub 2022 Apr 7. Erratum in: *Lancet Gastroenterol Hepatol*. 2022 Aug;7(8):704. PMID: 35397795; PMCID: PMC9192760.
- [10]Burnett-Hartman AN, Lee JK, Demb J, Gupta S. An Update on the Epidemiology, Molecular Characterization, Diagnosis, and Screening Strategies for Early-Onset Colorectal Cancer. *Gastroenterology*. 2021 Mar;160(4):1041-1049. doi: 10.1053/j.gastro.2020.12.068. Epub 2021 Jan 5. PMID: 33417940; PMCID: PMC8273929.
- [11]Spaander MCW, Zauber AG, Syngal S, Blaser MJ, Sung JJ, You YN, Kuipers EJ. Young-onset colorectal cancer. *Nat Rev Dis Primers*. 2023 Apr 27;9(1):21. doi: 10.1038/s41572-023-00432-7. PMID: 37105987; PMCID: PMC10589420.
- [12]Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. *CA Cancer J Clin*. 2023 May-Jun;73(3):233-254. doi:

10.3322/caac.21772. Epub 2023 Mar 1. PMID: 36856579.

- [13]Half EE, Levi Z, Mannalithara A, Leshno M, Ben-Aharon I, Abu-Freha N, Silverman B, Ladabaum U. Colorectal cancer screening at age 45 years in Israel: Cost-effectiveness and global implications. *Cancer*. 2024 Mar 15;130(6):901-912. doi: 10.1002/cncr.35097. Epub 2024 Jan 5. PMID: 38180788.
- [14]Howren A, Sayre EC, Loree JM, Gill S, Brown CJ, Raval MJ, Farooq A, De Vera MA. Trends in the Incidence of Young-Onset Colorectal Cancer With a Focus on Years Approaching Screening Age: A Population-Based Longitudinal Study. *J Natl Cancer Inst*. 2021 Jul 1;113(7):863-868. doi: 10.1093/jnci/djaa220. PMID: 33492399; PMCID: PMC8246802.
- [15]Jiang T, Li J, Meng L, Wang J, Zhang H, Liu M. Effects of transcutaneous electrical acupoint stimulation on gastrointestinal dysfunction after gastrointestinal surgery: A meta-analysis. *Complement Ther Med*. 2023 May;73:102938. doi: 10.1016/j.ctim.2023.102938. Epub 2023 Feb 25. PMID: 36842636.
- [16]Li AY. *Shennong's Classic of Materia Medica (Illustrated Edition)*. Beijing: Minzhu yu jianshe chubanshe; 2021: 207.
- [17]World Health Organization. WHO traditional medicine strategy: 2014-2023 [Internet]. World Health Organization; 2013 May 15. Available from: <https://www.who.int/publications/i/item/9789241506096>
- [18]Li DT, Wu XZ, He JL, Tang HM, Zhang LJ, Qiu ZW. Transdermal Drug Release Characteristics of Wuzhuyu Alkaloids and Wuzhuyu Alkaloids Determined by in vivo Skin Microdialysis Technique and HPLC. *Chin Pharm J*. 2015;03:239-243.

- [19]Gu Q, Wei XC, Liu L, Liang Y, Li J, Dong J, Cai XY, Gu W, Chen J.
Exploration of the Pharmacological Substance Basis and Potential Molecular
Mechanism of External Application of Volatile Oil of Pungent and Hot
Chinese Medicine Based on Network Pharmacology. *Chin Tradit Herb Drugs*.
2021;05:1383-1392.
- [20]von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP;
STROBE Initiative. The Strengthening the Reporting of Observational Studies
in Epidemiology (STROBE) statement: guidelines for reporting observational
studies. *PLoS Med*. 2007 Oct 16;4(10):e296. doi:
10.1371/journal.pmed.0040296. PMID: 17941714; PMCID: PMC2020495.
- [21]STROBE. STROBE Checklist: cohort studies [Internet]. [Accessed in 2024].
Available from: <https://www.strobe-statement.org/checklists/>
- [22]National Health Commission of the People's Republic of China; Chinese Society
of Oncology. [Chinese Protocol of Diagnosis and Treatment of Colorectal
Cancer (2023 edition)]. *Zhonghua Wai Ke Za Zhi*. 2023 Aug 1;61(8):617-644.
Chinese. doi: 10.3760/cma.j.cn112139-20230603-00222. PMID: 37400205.
- [23]Duhamel A, Labreuche J, Gronnier C, Mariette C. Statistical Tools for
Propensity Score Matching. *Ann Surg*. 2017;265(6):E79-E80.
doi:10.1097/SLA.0000000000001312
- [24]Bangalore S, Guo Y, Samadashvili Z, Blecker S, Xu J, Hannan EL. Everolimus-
eluting stents or bypass surgery for multivessel coronary disease. *N Engl J Med*.
2015;372(13):1213-1222. doi:10.1056/NEJMoa1412168
- [25]Gu HQ. Statistical approaches and figures for sensitivity analysis in clinical
research: a systematic review. *Chin J Evid-Based Cardiovasc Med*. 2018. doi:

10.3969/j.issn.1674-4055.2018.10.04.

- [26]Austin PC. The relative ability of different propensity score methods to balance measured covariates between treated and untreated subjects in observational studies. *Med Decis Making*. 2009 Nov-Dec;29(6):661-77. doi: 10.1177/0272989X09341755. Epub 2009 Aug 14. PMID: 19684288.
- [27]Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. *Multivariate Behav Res*. 2011 May;46(3):399-424. doi: 10.1080/00273171.2011.568786. Epub 2011 Jun 8. PMID: 21818162; PMCID: PMC3144483.
- [28]Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. *Ann Surg Oncol*. 2010 Jun;17(6):1471-4. doi: 10.1245/s10434-010-0985-4. PMID: 20180029.
- [29]Chinese Pharmacopoeia Commission. Chinese Pharmacopoeia [Internet]. 10th ed. Beijing: China Medical Science Press; 2020 [cited 2024 Mar 20].
- [30]Liang BX, Yuan TH, Yan C, Wang LJ, Xian SX. On the Traditional Chinese Medicine Connotation of Navel Therapy. *Chin J Tradit Chin Med*. 2018;10:4329-4332.
- [31]Liang C, Deng HY, Zheng LP, Liu D, Zhang YJ, Wu XF, Yuan JH. [Clinical observation of traditional Chinese medicine application on umbilical region for treating opioid-induced constipation]. *Chin J Clin Physician*. 2017;45(7):119-121.
- [32]Li YH, Tao J. The effect of abdominal acupoint application therapy on the recovery of gastrointestinal function in patients with acute intestinal obstruction. *Modern Journal of Integrated Traditional Chinese and Western Medicine*.

2020;(01):87-91.

- [33]Lv SW, Pan SW, Fu QF, Guo YY, Sun S, Li YJ. Development overview and prospects of navel drug delivery formulations. *Chin J Tradit Chin Med*. 2015;06:109-112. doi:10.19664/j.cnki.1002-2392.2015.06.037.
- [34]Feng L, Ding MH, Shen Q, Sun QH, Shi SL. Factors affecting the percutaneous permeability of rhein at the Shenque acupoint: a study on preliminary mechanisms. *Chin J Tradit Chin Med*. 2016;08:1546-1552.
- [35]Li X, Shen Y, Pan G, Peng H. Effects of moxibustion with Wuzhuyu on gastrointestinal motility and gastrointestinal hormone secretion in patients after abdominal surgery. *J Anhui Univ Chin Med*. 2024;02:28-31.
- [36]Wang S, Lei XJ, Zhu WF, Huang ZG. Study on in vitro percutaneous absorption of vinegar-modified Wu Zhu Yu powder. *Chin J Exp Tradit Med Form*. 2013;10:31-34.
- [37]Chen Z, Cao L, Wen Z, Cui N, Li N, Xie J, Tan Z, Luo Z, Wang S, Qin Y, Chen X, Xu Z, Ou A, Shang W, Jiang Z, Chen Q. Study of Evodia hot compress plus electro-acupuncture in patients who have undergone abdominal surgery. *Int J Clin Exp Med*. 2015 Sep 15;8(9):16167-74. PMID: 26629130; PMCID: PMC4659019.
- [38]Jian L. Application of Traditional Chinese Medicine External Treatment in the Combination of Laparoscopic and Open Surgery for Rapid Recovery Surgery in Colorectal Cancer [master's thesis]. Guangzhou University of Chinese Medicine; 2010. Available from: https://kns.cnki.net/kcms2/article/abstract?v=eoCTaIZmBOOI02BJaiSkM9x5UbjWb3bIFw3CQ_YnXnl9HVFfsAG_0tChqZ1cSOuYxqOmNeUDGmxlpvo1Iey1-JOTRJHj5PUwJKC0wu97m52osQoRbfKb38C-

SR2Mwo6lnqxtUSxU1BV4vsVU0FUmkYA==uniplatform=NZKPTlanguage
=CHS.

- [39]Wu JP, Ouyang FJ, Li ZS, Wu YR. Observation on the Effect of Enhanced Recovery Surgical Nursing Combined with Wuzhuyu Hot Compress External Application on Patients after Laparoscopic Appendectomy. *J Baotou Med Coll.* 2020;11:86-89. doi:10.16833/j.cnki.jbmc.2020.11.024
- [40]Yu J, Zhang ZJ, Liu YR. Effects of external application of Wuzhuyu on gastrointestinal function and inflammatory markers in patients after colon cancer surgery. *J External Ther Tradit Chin Med.* 2021;06:7-8.
- [41]Zhu CH, Zhou ZZ. Effects of wuzhuyu fumigation combined with acupoint massage on postoperative abdominal distention and pain in patients with uterine fibroids undergoing laparoscopic surgery. *J Jiangxi Univ Tradit Chin Med.* 2022;05:56-59.
- [42]Wen HJ, Wang JH, Zeng MF, Tan FN, Xie WJ. Effects of meridian acupoint massage combined with Wuzhuyu coarse salt hot compress on gastrointestinal function recovery after rectal cancer surgery. *Syst Med.* 2023;20:124-127. doi:10.19368/j.cnki.2096-1782.2023.20.124.
- [43]Li L, Wei RL, Cao H, Wei LJ, Shen JW, Sun M, Wang GL. Effects of Wuzhuyu coarse salt hot compress on gastrointestinal function recovery in patients with colorectal cancer after surgery under the guidance of enhanced recovery surgical concept. *Colorectal Anal Surg.* 2021;5:508-510+514. doi:10.19668/j.cnki.issn1674-0491.2021.05.025.
- [44]Zhang LQ, Zhang QS, Hu Y. Application of Pain Care Combined with Wuzhuyu Hot Compress in Postoperative Patients of Urological Laparoscopy. *Gen Nurs.* 2015;24:2374-2376.

- [45]Li LQ, Luo JY, Zhou XD, Chen PQ, Hu HQ, Liu Y, Zhang LJ. Efficacy analysis of hot compress with *Evodia rutaecarpa* combined with ultrasonic conductivity meter in promoting gastrointestinal function recovery in patients undergoing gastrointestinal surgery. *Med Pharm High Vocat Educ Mod Nurs*. 2023;(06):500-502+507.
- [46]Xu LG. Perioperative Application of Moxibustion and Hot Compress in Laparoscopic Cholecystectomy. *J Pract Tradit Chin Med*. 2013;03:150-153.
- [47]Chen Y, Gan Q, Zhang YH, Tang LP, Xiong ZF. Application effect of wuzhuyu hot compress combined with ear acupoint pressing beans in patients after laparoscopic surgery in urology department. *J Pract Clin Med*. 2023;06:74-77+91. doi:10.13764/j.cnki.lcsy.2023.06.019.
- [48]Qu HH, Qu XL, Li M. Study on the efficacy of Wuzhuyu abdominal hot compress combined with acupuncture at Zusanli point in promoting rapid recovery after laparoscopic surgery for colorectal cancer. *Chin J Med Pharm*. 2021;06:175-177+181.

533

534

535

536

537

A total of 1,480 inpatients diagnosed with colorectal cancer in the SAHGUCM from December 2016 to December 2022 were retrieved.

1) Meeting the diagnostic criteria for CRC in the 2017 edition of the Chinese Norms for the Diagnosis and Treatment of CRC [22], and further confirmed by pathological biopsy;
2) All participants underwent elective standard laparoscopic radical tumour curettage;
3) The age of the patients was between 25 and 80 years old;
...

1) Distant metastasis of the tumour;
2) Combination with other malignant tumours;
3) Physical disability that prevents them from co-operating with functional exercises;
...



455 cases included

Exclude outliers from data:
1 case of duplicate data

454 cases of valid data

Before PSM

After PSM

267 cases in ER group
187 cases in non-ER group

160 cases in ER group
160 cases in non-ER group

Fig. 1

Distribution of Propensity Scores




Fig. 2




Fig. 3







Fig. 4